VP02

VP02 is Vicore Pharma's preclinical **inhaled thalidomide** program, designed as a new formulation and local lung-delivery route for the immunomodulatory imide drug thalidomide in idiopathic pulmonary fibrosis. The rationale was to achieve high pulmonary exposure with reduced systemic exposure, with the aim of addressing both **IPF-associated severe cough** and potentially underlying lung disease biology in interstitial lung disease. Mechanistically, VP02 leverages thalidomide's broad immunomodulatory and anti-inflammatory pharmacology, but the specific intended molecular target profile for this inhaled formulation was not clearly disclosed in the cited company materials. The program advanced through formulation optimization and preclinical toxicology preparation, but Vicore later disclosed that it would discontinue development of the preclinical inhaled thalidomide program in order to prioritize other pipeline assets.

Other names

inhaled thalidomidethalidomide inhalationinhaled IMiD